The Lancet Group

Just published in The Lancet Group: “Gender and global health: going, going but not gone” - a searing new commentary co-authored by Prof. Sarah Hawkes and Prof. Kent Buse of Global 50/50, alongside Commissioners and authors of the Lancet Commission on Gender and Global Health. As the commentary warns, we are witnessing a wave of regressive, anti-gender ideologies spreading across the globe - well-funded, politically coordinated, and increasingly powerful. From erasing the term “gender” from US federal departments to dismantling entire ministries, this backlash is not abstract - it’s policy, power, and practice. “Banning words captures headlines but the consequences of the anti-gender ideology are also reflected in major policy shifts in a number of countries.” This commentary provides vital political and historical context for the work and recommendations of the Lancet Commission on Gender and Global Health—illuminating why now, more than ever, a global movement for gender justice in health is urgently needed. It calls on all of us to: ✔️ Defend feminist and democratic values ✔️ Tackle disinformation and restore trust in science ✔️ Insist that governments respect, protect, and fulfil universal rights ✔️ Resource and uphold accountable institutions “This is not the time to retreat. It is the time to organise, resist, and act.” Read the full commentary here: https://lnkd.in/dQKygBKj Then share it widely. The stakes are too high. Co-authors: Sarah Hawkes, Raewyn Connell, Jocalyn Clark, Jeni Klugman, Gary Darmstadt, Erica Nelson, Amy H., Elhadj As Sy, Gary Barker, PhD, Ben C., Kent Buse 📸 Image Credit: Anwar Sadat Swaka #GenderAndGlobalHealth #GenderJustice #GlobalHealth #HealthEquity #WorldHealthDay

🌍✨ The pursuit of #GenderJustice in global health is not simply an aspiration—it’s a necessity for improving health outcomes and addressing inequities. A new Lancet Commission: ✅ Examines the historical and social factors that inform the relationship between gender and health ✅ Identifies the obstacles posed by groups resisting progress ✅ Presents clear, evidence-based recommendations for integrating a gender justice perspective into health policies and practices (see infographic below) “Gender justice in health depends on our collective resolve for action to advance and defend feminist and democratic principles, to tackle disinformation and to demand that all governments protect universal human rights. The 99% who will pay the price of the anti-gender ideology must be persuaded to come together under more unifying agendas”, says Commission co-chair Professor Sarah Hawkes. 📖 Explore the Commission in full: https://hubs.li/Q03g3XG30 #GlobalHealth #HealthEquity #TheLancet #WorldHealthDay #GenderAndGlobalHealth

📃 Facts and myths about #measles “Measles is a ‘canary in the coalmine’ for under-vaccination, be it due to vaccine misinformation, lack of access to vaccination, or conflict [...] knowing the facts about measles information and disinformation is key.” Read and share the The Lancet Infectious Diseases’ April Editorial ➡️ hubs.ly/Q03g21Pp0

🔔 Stay tuned! On Monday, April 7, we will launch the highly anticipated Lancet Commission on Gender and Global Health. In the meantime, get a sneak peek into the Commission report by reading this announcement Comment: https://lnkd.in/dHpB3ACP #GenderAndGlobalHealth

Reducing Postpartum Haemorrhage: This Week’s Cover Story in The Lancet 📘 While great strides in reducing maternal mortality were made in the early 21st century, progress has slowed over the past decade, and we are not on track to meet the Sustainable Development Goal of reducing maternal deaths by 2030. However, effective interventions are available to decrease morbidity and mortality from postpartum hemorrhage (PPH), and recent advancements offer reasons for optimism. As we approach #WorldHealthDay on April 7, the WHO is launching a year-long campaign titled “Healthy Beginnings, Hopeful Futures.” This initiative aims to reignite global efforts to ensure that women and babies have access to high-quality care 🌎 Find out more in a new Editorial ➡️ hubs.li/Q03fVL090 Link to the full issue in the comments ⤵️ Cover quote: Bleeding due to postpartum haemorrhage...is the leading cause of maternal mortality, resulting in 70 000 deaths each year...a situation that demands concerted action.

Now, more than ever, the global scientific community must unite to protect research integrity and drive progress despite adversity.   “Europe can lead the way in upholding transparency and independence, and in promoting inclusive research” Announcing a new landmark collaboration between The Lancet Regional Health – Europe and the European Medicines Agency. Together, we aim to ✅ strengthen transparency in medical science, ✅ foster knowledge exchange, ✅ reinforce European leadership in research integrity & medical innovation As part of this collaboration, The Lancet Regional Health – Europe will publish News pieces from the EMA every 2 months, offering timely updates on newly approved drugs in the EU. Read an Editorial: https://lnkd.in/eW89eTeZ   Explore a News piece: https://lnkd.in/eA3vE_Xs   Alt: Cover of The Lancet Regional Health – Europe’s April 2025 issue. Image on cover is a European Union flag flowing in the wind. Underneath the flag are silhouettes of people standing at a railing looking up at it.

🏳️⚧️March 31 is transgender day of visibility. Transgender, non-binary, and gender diverse (trans) people face a disproportionate and substantial burden of HIV. With multiple systemic factors contributing to risk of HIV acquisition and barriers to prevention, testing, and treatment. 🏳️⚧️The Lancet HIV has marked Transgender Day of Visibility by publishing a Personal View by Sari Reisner (University of Michigan, Ann Arbor, MI, USA) on the Situated Vulnerabilities and Resiliencies Framework, which describes and explains HIV inequities faced by trans populations. The framework highlights the need for integrated strategies and interventions that are neutral to HIV status and grounded in health and human rights, work with trans communities, and use strengths-based approaches leveraging situated resiliencies to reduce pervasive stigma and advance HIV equity in trans populations. 📰 Read the Personal View here https://lnkd.in/erkntBwK 🏳️⚧️We also publish research from Reisner and colleagues reporting data from the LEGACY cohort: the study shows that gender-affirming care is important for optimising HIV outcomes among trans people. Trans people receiving gender-affirming hormone therapy in this study had 37% lower risk of HIV acquisition and 44% lower risk of viral non-suppression compared with those not receiving hormone therapy. 📰 Read the research here: https://lnkd.in/eCNb3JFU 🎧 In our March podcast, Sari Reisner joins us to discuss his work: https://lnkd.in/eV_raRBw 🏳️⚧️It is essential to recognise trans men and women, non-binary, and gender-diverse populations in the HIV response. Providing social and medical support for trans people to access stigma-free gender-affirming care is essential to ensuring positive HIV outcomes. On Transgender Day of Visibility, we express our support and allyship to trans communities. #tdov #transdayofvisibility #transgender #trans #lgbtq #transgenderdayofvisibility #HIV #publichealth #globalhealth #humanrights

💬 "Uneven and Disappointing" Despite their proven effectiveness, uptake of WHO best buys for combating non-communicable diseases (NCDs) has been uneven and disappointing, as highlighted by the authors of a new Health Policy in The Lancet Regional Health – Europe. However, a range of "quick buys" could drive measurable public health impacts within just five years ✅ After evaluating 49 cost-effective interventions (each costing less than $120,000 per disability-adjusted life-year averted), 25 were identified as quick buys, including those relating to: 🔹 Tobacco (5 interventions) 🔹 Alcohol (4 interventions) 🔹 Unhealthy diet (3 interventions) 🔹 Physical inactivity (1 intervention) 🔹 Cardiovascular disease (3 interventions) 🔹 Diabetes (4 interventions) 🔹 Chronic respiratory disease (1 intervention) 🔹 Cancer (4 interventions) According to Gauden Galea and colleagues, “These findings not only provide valuable guidance for policymakers navigating short-term political cycles but also have the potential to accelerate progress toward global health targets.” Discover the full set of interventions here ➡️ https://hubs.ly/Q03f2XnQ0 Alt: Left, the first page of the Health Policy. Right, Lancet editor Heather Brown speaks at the WHO/Europe launch of the Health Policy.

🔔 We are pleased to announce The Lancet Obstetrics, Gynaecology, & Women’s Health! ⬇️

Lancet weekly highlights ✨ 1️⃣ Almost 40 years ago, the discovery of the vasoactive neuropeptide calcitonin gene-related peptide (CGRP) and its role in migraine pathophysiology ushered in a new era in migraine treatment. Since 2018, monoclonal antibodies (mAbs) targeting the CGRP pathway are available for migraine prevention. What next? On the cover of The Lancet, a Therapeutics paper. 🔗 https://hubs.li/Q03cTyL50 2️⃣ “The sweeping chaotic and ill-considered unilateral halt of global health programmes is no way to institute reforms.” Our editors discuss the demise of USAID and rethinking foreign aid in a turbulent climate. Read a new Editorial. 🔗 https://hubs.li/Q03cTyL50 3️⃣ After a series of senior departures from NHS England, the UK Prime Minister has caused shockwaves by abolishing the body entirely, Jacqui Thornton reports. 🔗 https://hubs.li/Q03cTyrF0 📘 Find this content and more in the March 22 issue of The Lancet: https://hubs.li/Q03cTwSJ0 Alt: Cover of The Lancet, March 22 issue. The cover quote says, “Drugs targeting the CGRP pathway represent a mechanism-specific approach to both acute and preventive migraine treatment with a proven efficacy and an excellent safety and tolerability profile.”